title: Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects.
abstract: OBJECTIVE
  Bilastine is a novel second-generation antihistamine for the symptomatic treatment of allergic rhinitis and urticaria. The objective of this study was to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of bilastine following single and multiple oral doses in healthy Japanese subjects. The pharmacokinetic and pharmacodynamic profiles were compared with those reported in Caucasian subjects.
  
  
  METHODS
  In a single-blind, randomized, placebo-controlled, parallel-group, single- and multiple-ascending dose study, bilastine tablets were administered at single doses of 10, 20, and 50 mg (Part I), and once daily for 14 days at 20 and 50 mg (Part II).
  
  
  RESULTS
  After single oral doses, maximum plasma concentrations (Cmax) were reached at 1.0-1.5 h postdose. Plasma exposure [Cmaxand area under the plasma concentration-time curve (AUC)] increased dose-proportionally at single doses of 10-50 mg. In repeated-dose administration, no remarkable differences were observed between Day 1 and Day 14 for Cmaxor AUC. For inhibitory effects on wheal and flare response, bilastine 20 and 50 mg showed significant inhibition from 1.5 h after administration as compared with placebo, and the significant effect persisted for 24 h after administration. The rates of adverse events (AEs) were comparable between bilastine and placebo in both Part I and Part II. In addition, no dose- or administration period-dependent tendency of increase in rate of AEs or worsening of severity was observed.
  
  
  CONCLUSIONS
  Bilastine exhibits similar single- and multiple-dose pharmacokinetic and pharmacodynamic characteristics in healthy Japanese subjects compared with those observed in Caucasian subjects in previous studies.
authors: Project Management Department, TAIHO Pharmaceutical Co., Ltd., 1-2-4, Uchikanda, Chiyoda-ku, Tokyo, 101-0047, Japan. mtogawa@taiho.co.jp.
authors: Michinori
authors: http://orcid.org/0000-0003-1229-3261
authors: M
authors: Togawa
authors: Tsukuba Research Center, TAIHO Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan.
authors: Hidetoshi
authors: H
authors: Yamaya
authors: Drug Modeling and Consulting, DynaKin, S.L. Bizkaia Technology Park, 48160, Derio, Vizcaya, Spain.
authors: Mónica
authors: M
authors: Rodríguez
authors: Shinjuku Research Park Clinic, 1-22-17, Hyakunin-cho, Shinjuku-ku, Tokyo, 169-0073, Japan.
authors: Hirotaka
authors: H
authors: Nagashima
mesh_terms: D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D039563:Histamine H1 Antagonists, Non-Sedating / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology; D016037:Single-Blind Method; D055815:Young Adult
chemical_list: D001562:Benzimidazoles; D039563:Histamine H1 Antagonists, Non-Sedating; D010880:Piperidines; C445659:bilastine